Literature DB >> 16985907

Early Response Time in Sexual Activity and Mood Following Testosterone Gel Replacement in Hypogonadal Males from the Testim(R) START Study.

Edward Loizides, Mark J Swierzewski, Carol O'neill, Jim Griesser, Ted Smith.   

Abstract

Sexual activity, sexual desire, and mood decrease in men with low testosterone levels. The Testim(R) Study of Testosterone Androgen Response Time (START) explored the time to response in sexual activity, desire, and mood following testosterone replacement therapy with Testim for 30 days in 638 hypogonadal men. Response in sexual activity, desire, and mood all improved relative to baseline within the first week of Testim therapy. Patients reached a maximal response by the end of 2 weeks of therapy and maintained the response through 4 weeks of therapy. Frequency of intercourse showed a significant increase after 2 weeks of Testim therapy. Both measures of positive mood and negative mood improved significantly, beginning with the first week of therapy and reaching and maintaining a maximal response at the second week.

Entities:  

Year:  2004        PMID: 16985907      PMCID: PMC1472879     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  7 in total

Review 1.  Andropause: clinical implications of the decline in serum testosterone levels with aging in men.

Authors:  Alvin M Matsumoto
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-02       Impact factor: 6.053

2.  A simple self-report diary for assessing psychosexual function in hypogonadal men.

Authors:  Ka Kui Lee; Nancy Berman; Gerianne M Alexander; Laura Hull; Ronald S Swerdloff; Christina Wang
Journal:  J Androl       Date:  2003 Sep-Oct

3.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men.

Authors:  C Wang; R S Swerdloff; A Iranmanesh; A Dobs; P J Snyder; G Cunningham; A M Matsumoto; T Weber; N Berman
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

5.  A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.

Authors:  T A McNicholas; J D Dean; H Mulder; C Carnegie; N A Jones
Journal:  BJU Int       Date:  2003-01       Impact factor: 5.588

6.  Characterization of patients in a medical endocrine-based center for male sexual dysfunction.

Authors:  A T Guay; E Velasquez; J B Perez
Journal:  Endocr Pract       Date:  1999 Nov-Dec       Impact factor: 3.443

7.  AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function.

Authors:  C Steidle; S Schwartz; K Jacoby; T Sebree; T Smith; R Bachand
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

  7 in total
  6 in total

Review 1.  What are critical outcome measures for patients receiving pituitary replacement following brain injury?

Authors:  Sorin G Beca; Walter M High; Brent E Masel; Kurt A Mossberg; Randall J Urban
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

Review 2.  When and when not to use testosterone for palliation in cancer care.

Authors:  Rony Dev; Eduardo Bruera; Egidio Del Fabbro
Journal:  Curr Oncol Rep       Date:  2014-04       Impact factor: 5.075

Review 3.  The dominance behavioral system and psychopathology: evidence from self-report, observational, and biological studies.

Authors:  Sheri L Johnson; Liane J Leedom; Luma Muhtadie
Journal:  Psychol Bull       Date:  2012-04-16       Impact factor: 17.737

Review 4.  Topical testosterone supplementation for the treatment of male hypogonadism.

Authors:  Katrina A Abadilla; Adrian S Dobs
Journal:  Drugs       Date:  2012-08-20       Impact factor: 9.546

Review 5.  Selective androgen receptor modulators for the treatment of late onset male hypogonadism.

Authors:  Christopher C Coss; Amanda Jones; Michael L Hancock; Mitchell S Steiner; James T Dalton
Journal:  Asian J Androl       Date:  2014 Mar-Apr       Impact factor: 3.285

Review 6.  Safety and efficacy of testosterone gel in the treatment of male hypogonadism.

Authors:  Kishore M Lakshman; Shehzad Basaria
Journal:  Clin Interv Aging       Date:  2009-11-18       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.